CONCORD NEWS IN YOUR INBOX: SIGN UP HERE

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

113.43 +1.27 (+1.13%)
Streaming Delayed Price Updated: 2:03 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case ↗
Via Chartmill
Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗
Via Stocktwits
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report ↗
Via Stocktwits
News headline image
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗
When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation. 
Via Stocktwits
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
All three companies are in better shape than most investors are (understandably) presuming. 
Via The Motley Fool
Topics Bonds
News headline image
1 Momentum Stock Worth Your Attention and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
Why Revolution Medicines Stock Surged by 11% Today ↗
The company might become the latest biotech acquisition story soon. 
Via The Motley Fool
Topics Intellectual Property
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗
Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32... 
Via Benzinga
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
American Trade Resilience: Deficit Hits 17-Year Low as Export Surge and Tariff Shocks Reshape Global Commerce
In a landmark shift for the American economy, the U.S. trade deficit has plummeted to its lowest level in 17 years, signaling a profound transformation in global supply chains and domestic production.... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
News headline image
Neogen Shares Skyrocket as Q2 Earnings Beat Signals Turning Point in 3M Integration Strategy
LANSING, MI – Shares of Neogen Corporation (NASDAQ: NEOG) experienced a dramatic surge in early trading today, climbing nearly 29% after the food and animal safety leader reported second-quarter fiscal... 
Via MarketMinute
Topics Earnings Economy
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands... 
Via MarketMinute
Topics Economy
News headline image
3 Drug Stocks to Buy at a Discount ↗
The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider. 
Via The Motley Fool
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the... 
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Complete Acquisition of Cidara Therapeutics
From Merck Sharp & Dohme
Via Business Wire
News headline image
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
From Merck & Co., Inc.
Via Business Wire
News headline image
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK ↗
In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article